Boiron : CA T3 2023 inférieur à notre attente - Boiron n’évoque plus de ROP 2023 en hausse - Apport du bloc majoritaire à Boiron Développement
>T3 : -5,7% et -2,8% hors COVID - Boiron a publié un CA T3 à 121 M€ soit un recul de 5,7% et -2,8% si l’on retraite des ventes COVID.En cumul à 9 mois, le CA se réduit de 6,3%, impactées par l'effet de base provenant des ventes importantes de tests COVID réalisées en France sur l'année 2022. Hors tests COVID, les ventes sont en hausse de 3%. Cette croissance se répartit l'ensemble des zones géographiques et est portée par les ventes de spécialités homéopathiques....Boiron manufactures and markets homeopathic medicines. Homeopathic medicines are prepared from vegetable, animal, mineral, or chemical substances, which are diluted. Co. sells three types of products in 59 countries: Non-proprietary homeopathic medicines, OTC family medication specialties, and Other products. There are two large families of homeopathic medicines: Those associated with precise therapeutic indications and dosage, and those that do not mention a therapeutic indication or dosage. Co. supports homeopathy education and training organizations for healthcare professionals. Some of Co.'s brand names include Oscillococcinum®, Stodal®, S?datif PC®, and Coryzalia.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.